Author details

Full Name

Karen E Sheppard

Affiliation

ORCID

Career Start Year

1986

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36722142	Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.	Mol Cancer Ther	2023
37917641	PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.		2023
36967556	The therapeutic potential of targeting minimal residual disease in melanoma.	Clin Transl Med	2023
35232962	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma.	Nat Commun	2022
35444175	Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?	NPJ Precis Oncol	2022
34944961	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.	Cancers (Basel)	2021
33572972	CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF<sup>V600</sup> Melanoma via a p53 Dependent Pathway.	Cancers (Basel)	2021
33990344	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory.	Cancer Discov	2021
34025662	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.	Front Immunol	2021
33303574	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.	Cancer Immunol Res	2021
33173151	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.	Br J Cancer	2021
34680285	PRMT5: An Emerging Target for Pancreatic Adenocarcinoma.	Cancers (Basel)	2021
34625515	Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).	J Immunother Cancer	2021
34830962	Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies.	Cancers (Basel)	2021
34375607	Is resistance to targeted therapy in cancer inevitable?	Cancer Cell	2021
32719798	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.	Frontiers in Cell and Developmental Biology	2020
32549336	Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?	Cancers (Basel)	2020
33046726	Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF<sup>V600</sup> melanoma cells.	Sci Data	2020
31439820	Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.	Proc Natl Acad Sci U S A	2019
31692881	CDK4/6 inhibition in cancer: the cell cycle splicing connection.	Molecular and Cellular Oncology	2019
31092402	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.	Cancer Discov	2019
30718660	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.	Sci Rep	2019
29243224	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naÃ¯ve melanoma but not after the development of BRAF inhibitor resistance.	Int J Cancer	2018
27989772	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription.	Gene	2017
27340778	Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.	Oncotarget	2016
27391441	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.	Oncotarget	2016
26286024	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.	Sci Signal	2015
25544760	Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.	Oncotarget	2015
25790252	Unexpected role of CDK4 in a G2/M checkpoint.	Cell Cycle	2015
25852062	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.	Mol Cancer Ther	2015
24469106	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.	Cancer Discov	2014
24495407	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment Cell Melanoma Res	2014
23362323	Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.	Clin Cancer Res	2013
24336498	Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.	Sci Rep	2013
24011934	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.	Eur J Cancer	2013
24009430	AKT-independent PI3-K signaling in cancer - emerging role for SGK3.	Cancer Management and Research	2013
24089445	The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.	Clin Cancer Res	2013
22214849	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.	J Clin Invest	2012
22896685	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.	Cancer Res	2012
22471665	Targeting PI3 kinase/AKT/mTOR signaling in cancer.	Crit Rev Oncog	2012
21878679	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	Sci Signal	2011
21533284	Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.	PLoS One	2011
20919962	Second AKT: the rise of SGK in cancer signalling.	Growth Factors	2010
16533503	Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.	Cardiovascular Research	2006
15665058	Regression of pressure overload-induced left ventricular hypertrophy in mice.	American Journal of Physiology - Heart and Circulatory Physiology	2005
14676212	UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide.	Journal of Biological Chemistry	2004
12852253	Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart.	Vitamins and Hormones	2003
11751610	11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart.	Endocrinology	2002
11960770	Nuclear receptors. II. Intestinal corticosteroid receptors.	American Journal of Physiology - Gastrointestinal and Liver Physiology	2002
10960352	Novel nuclear corticosteroid binding in rat small intestinal epithelia.	American Journal of Physiology - Gastrointestinal and Liver Physiology	2000